SCHEMBL4155501

SCHEMBL4155501

[O]CCNc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 2/20 0.41
RHOC P08134 2/20 0.41
RHOA P61586 2/20 0.41
HDAC1 Q13547 1/20 0.41
FFAR1 O14842 1/20 0.41
NPC1 O15118 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
CNR1 P21554 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154942 0.86 RHOC (0.45) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL9639726 0.85 MAPT (0.55) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL1947326 0.78 MEN1 (0.47) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL3029679 0.78 MEN1 (0.47) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL4149063 0.78 RPS6KA2 (0.44) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL296404 0.76 HPGD (0.46) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL1801536 0.76 NR1I2 (0.56) MEN1KMT2AMAPTGAANPC1
SCHEMBL423851 0.76 MEN1 (0.46) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL656024 0.76 STK17A (0.50) MEN1KMT2AMAPTGAARHOC
SCHEMBL11528235 0.76 MAPT (0.58) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS LABORATORIOS SALVAT, S.A. (ES) 2009-04-02 US disclosed
US-7423172-B2 Tyrosine derivatives as PPAR-γ-modulators LABORATORIOS SALVAT, S.A. (ES) 2008-09-09 US disclosed
US-20070276043-A1 Tyrosine Derivatives As Ppar-Gamma-Modulators LABORATORIES SALVAT, S.A. (ES) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS PPARG, PPARD, TYRO3 MEN1 4879/4885KMT2A 2852/4885MAPT 2739/4885
US-20070276043-A1 Tyrosine Derivatives As Ppar-Gamma-Modulators PPARG, PPARD, PPARA MEN1 4879/4885KMT2A 2792/4885MAPT 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.